[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Sharma et al., 2019 - Google Patents

Rapid selection and identification of functional CD8+ T cell epitopes from large peptide-coding libraries

Sharma et al., 2019

View HTML @Full View
Document ID
4338635815097686784
Author
Sharma G
Rive C
Holt R
Publication year
Publication venue
Nature Communications

External Links

Snippet

Cytotoxic CD8+ T cells recognize and eliminate infected or malignant cells that present peptide epitopes derived from intracellularly processed antigens on their surface. However, comprehensive profiling of specific major histocompatibility complex (MHC)-bound peptide …
Continue reading at www.nature.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host

Similar Documents

Publication Publication Date Title
Sharma et al. Rapid selection and identification of functional CD8+ T cell epitopes from large peptide-coding libraries
Kula et al. T-Scan: a genome-wide method for the systematic discovery of T cell epitopes
Zhang et al. High-throughput determination of the antigen specificities of T cell receptors in single cells
Wroblewska et al. Protein barcodes enable high-dimensional single-cell CRISPR screens
JP7236543B2 (en) Methods and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
Joglekar et al. T cell antigen discovery via signaling and antigen-presenting bifunctional receptors
Bear et al. Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting
Dobson et al. Antigen identification and high-throughput interaction mapping by reprogramming viral entry
Ye et al. In vivo CRISPR screening in CD8 T cells with AAV–Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma
Graham et al. Antigen discovery and specification of immunodominance hierarchies for MHCII-restricted epitopes
Khodadoust et al. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens
Ott et al. An immunogenic personal neoantigen vaccine for patients with melanoma
Ma et al. High-throughput and high-dimensional single-cell analysis of antigen-specific CD8+ T cells
Hu et al. A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens
Davis et al. Interrogating the repertoire: broadening the scope of peptide–MHC multimer analysis
Gfeller et al. Improved predictions of antigen presentation and TCR recognition with MixMHCpred2. 2 and PRIME2. 0 reveal potent SARS-CoV-2 CD8+ T-cell epitopes
Yarmarkovich et al. Targeting of intracellular oncoproteins with peptide-centric CARs
Cattaneo et al. Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens
Gejman et al. Identification of the targets of T-cell receptor therapeutic agents and cells by use of a high-throughput genetic platform
Fink Can we improve vaccine efficacy by targeting T and B cell repertoire convergence?
Williamson et al. Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury
Ebrahimi-Nik et al. Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope
Pang et al. Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
Obermair et al. High-resolution profiling of MHC II peptide presentation capacity reveals SARS-CoV-2 CD4 T cell targets and mechanisms of immune escape
Mimitou et al. Scalable, multimodal profiling of chromatin accessibility and protein levels in single cells